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Summary
Background The number of individuals with vision impairment worldwide is increasing because of an ageing 
population. We aimed to systematically identify studies describing the association between vision impairment and 
mortality, and to assess the association between vision impairment and all-cause mortality.
Methods For this systematic review and meta-analysis, we searched MEDLINE (Ovid), Embase, and Global Health 
database on Feb 1, 2020, for studies published in English between database inception and Feb 1, 2020. We included 
prospective and retrospective cohort studies that measured the association between vision impairment and all-cause 
mortality in people aged 40 years or older who were followed up for 1 year or more. In a protocol amendment, we also 
included randomised controlled trials that met the same criteria as for cohort studies, in which the association 
between visual impairment and mortality was independent of the study intervention. Studies that did not report age-
adjusted mortality data, or that focused only on populations with specific health conditions were excluded. Two 
reviewers independently assessed study eligibility, extracted the data, and assessed risk of bias. We  graded the overall 
certainty of the evidence using the Grading of Recommendations, Assessment, Development and Evaluations 
framework. We did a random-effects meta-analysis to calculate pooled maximally adjusted hazard ratios (HRs) for 
all-cause mortality for individuals with a visual acuity of <6/12 versus those with ≥6/12; <6/18 versus those with ≥6/18; 
<6/60 versus those with ≥6/18; and <6/60 versus those with ≥6/60.
Findings Our searches identified 3845 articles, of which 28 studies, representing 30 cohorts (446 088 participants) 
from 12 countries, were included in the systematic review. The meta-analysis included 17 studies, representing 
18 cohorts (47 998 participants). There was variability in the methods used to assess and report vision impairment. 
Pooled HRs for all-cause mortality were 1·29 (95% CI 1·20–1·39) for visual acuity <6/12 versus ≥6/12, with low 
heterogeneity between studies (n=15; τ²=0·01, I²=31·46%); 1·43 (1·22–1·68) for visual acuity <6/18 versus ≥6/18, 
with low heterogeneity between studies (n=2; τ²=0·0, I²=0·0%); 1·89 (1·45–2·47) for visual acuity <6/60 versus ≥6/18 
(n=1); and 1·02 (0·79–1·32) for visual acuity <6/60 versus ≥6/60 (n=2; τ²=0·02, I²=25·04%). Three studies received 
an assessment of low risk of bias across all six domains, and six studies had a high risk of bias in one or more 
domains. Effect sizes were greater for studies that used best-corrected visual acuity compared with those that used 
presenting visual acuity as the vision assessment method (p=0·0055), but the effect sizes did not vary in terms of risk 
of bias, study design, or participant-level factors (ie, age). We judged the evidence to be of moderate certainty.
Interpretation The hazard for all-cause mortality was higher in people with vision impairment compared with those 
that had normal vision or mild vision impairment, and the magnitude of this effect increased with more severe vision 
impairment. These findings have implications for promoting healthy longevity and achieving the Sustainable 
Development Goals.
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Introduction
Over half a billion people are blind or have distance 
vision impairment worldwide.1 Blindness and vision 
impairment are most common among adults aged 
50 years and older, who account for more than 80% of 
people with vision loss.2 As populations continue to age, 
the prevalence of vision impairment and blindness are 
projected to more than double over the next 30 years.1 
The impacts of vision impairment and blindness are 
wide-reaching, including an increased risk of falls, 
cognitive impairment and dementia, depression, dis-
ability, and loss of independence.2,3 Some studies have 
also reported that vision impairment and blindness are 
associated with an increased risk of mortality.4
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In a previous meta-analysis, Zhang and colleagues4 
examined 29 studies that measured the association 
between vision impairment and mortality. Among these 
studies, 15 used objective measures of vision (eg, visual 
acuity), whereas others relied on self-reported visual 
difficulty, or vision impairment defined by International 
Classification of Diseases (ICD) codes. The risk of bias in 
these studies and the overall quality of evidence was 
not assessed.4 Since this meta-analysis was published 
in 2016, several additional primary studies have been 
published,5–10 including those done in previously under-
represented regions, such as sub-Saharan Africa5 and 
east Asia.6
An improved understanding of the association between 
vision impairment and mortality is needed to inform 
public policy, public health planning, and allocation of 
limited health-care resources. As part of The Lancet 
Global Health Commission on Global Eye Health,11 we 
Research in context
Evidence before this study
We searched PubMed on Feb 1, 2020, for primary research 
articles published in English from database inception up to 
Feb 1, 2020. A full list of the search terms used can be found in 
the appendix (pp 2–5). We identified a single meta-analysis of 
the association between vision impairment and mortality. 
This study analysed the association between vision 
impairment (measured by use of objective clinical instruments, 
self-reported visual difficulty, and administrative claims) and 
all-cause mortality. The results showed a significant association 
between mortality and the highest degree of vision impairment 
when compared with no vision impairment. The study did not 
include a narrative review of the literature, an assessment of the 
risk of bias in included studies, or an overall grading of the 
certainty of the evidence. We also found that, since the 
publication of this meta-analysis, several additional primary 
research articles had been published, and that some of these 
articles were from regions of the world, including sub-Saharan 
Africa and east Asia, that were previously not well represented 
in the literature.
Added value of this study
This systematic review and meta-analysis adds to the existing 
literature by including newly published articles investigating 
the association between vision impairment and all-cause 
mortality in adults worldwide. By conducting a full systematic 
review, we have identified opportunities for standardisation of 
data collection and reporting, and we found additional studies 
on the topic that could not be included in the meta-analysis due 
to the choice of vision impairment thresholds, the analytic 
methods used, or both. Additionally, we used the Quality in 
Prognostic Studies tool to assess the risk of bias in included 
studies, and the Grading of Recommendations, Assessment, 
Development and Evaluations (GRADE) framework to judge the 
overall certainty of the evidence. We also did meta-analyses 
comparing the hazard of all-cause mortality in participants with 
and without specified levels of visual acuity impairment. We 
found that the hazard of mortality was higher among 
participants with mild vision impairment (visual acuity <6/12) 
compared with those who had no vision impairment (≥6/12), 
and was higher in those with moderate vision impairment 
(<6/18) compared with those with no vision impairment or 
mild vision impairment (≥6/18). Among people with severe 
vision impairment or blindness (visual acuity <6/60), the 
hazard for mortality was higher than for those with normal 
vision or mild vision impairment. However, no association 
between vision impairment and mortality was observed when 
participants with a visual acuity of worse than 6/60 were 
compared with those with visual acuity of better than 6/60, 
probably because the reference group (ie, those with a visual 
acuity of ≥6/60) comprised a heterogeneous group of 
participants with moderate vision impairment, mild vision 
impairment, and normal vision. We assessed the robustness of 
our findings by examining heterogeneity in our effect 
estimates, performing meta-regressions, and testing for 
publication bias; we found little heterogeneity in our estimates 
and no evidence of publication bias. However, studies reported 
a significantly larger effect size if they assessed the association 
between mortality and best-corrected visual acuity rather than 
the association between mortality and presenting visual acuity.
Implications of all the available evidence
Our systematic review and meta-analysis highlights the 
prevailing finding that vision impairment is associated with a 
higher hazard of age-adjusted all-cause mortality in adults 
across diverse global settings and populations. Using the 
GRADE framework, we are moderately confident that the 
mortality risk associated with vision impairment reported in 
this study is likely to be close to the true value, but there is a 
possibility that the true hazard might be substantially different. 
Future research should focus on assessing the association 
between mortality and other clinical measures of vision (eg, 
visual field or contrast sensitivity) that have been shown to 
affect functioning, quality of life, and health outcomes. In 
addition, no studies on this topic have been conducted in 
eastern Europe, Latin America, the Caribbean, north Africa, or 
the Pacific islands, and data from these regions is important to 
improve the generalisability of study findings. Future 
calculations of disability-adjusted life-years might include years 
of life lost due to vision impairment, which could provide a 
more complete estimate of the overall global burden of vision 
impairment. As most vision impairment and blindness is 
avoidable or correctable, this study has important implications 
for optimising healthy longevity for populations worldwide, 
and for achieving the Sustainable Development Goals (SDGs), 
particularly SDG3, which aims to “ensure healthy lives and 
promote well-being for all at all ages”.
See Online for appendix
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therefore did an updated systematic review and meta-
analysis to assess the extent, strength, and quality of 
evidence on the association between vision impairment 
and age-adjusted all-cause mortality in adults worldwide. 
To provide a comprehensive assessment of the current 
state of scientific knowledge, we also examined the 
potential causes of variation in this association.
Methods
Search strategy and selection criteria
In this systematic review and meta-analysis, we searched 
MEDLINE (Ovid), Embase, and Global Health database 
on Feb 1, 2020, for studies published in English 
between database inception and Feb 1, 2020. We included 
prospective and retrospective cohort studies that 
measured the association between vision impairment 
and all-cause mortality in people aged 40 years or older, 
who were followed up for 1 year or more. In a protocol 
amendment, we included randomised controlled trials 
(RCTs), as long as the reported association between 
vision impairment and mortality was independent of the 
study intervention; we also included RCTs and cohort 
studies with participants younger than 40 years if more 
than 50% of participants were aged 40 years or older. We 
assessed the effect of these protocol amendments on 
effect estimates in meta-regression analyses. Conference 
abstracts and grey literature were not included. We 
identified additional studies by searching the reference 
lists of included studies. The searches were done by an 
information specialist (IG), and the search strategy and 
full list of search terms used are provided in the appendix 
(pp 2–5).
We intended to include studies in which vision was 
assessed by use of any objective clinical measure of 
vision and in which age-adjusted all-cause mortality was 
reported. We only included studies in the meta-analysis 
that assessed visual acuity, as few studies reported 
associations with other measures of vision (eg, contrast 
sensitivity or visual fields). In studies that used best-
corrected visual acuity and presenting visual acuity as 
vision assessment methods, data on best-corrected 
visual acuity were included in the primary analysis. 
Studies that did not report age-adjusted mortality, or 
that focused only on populations with specific health 
conditions (eg, diabetes or stroke) were excluded, as in 
such cases, age and systemic disease might have a strong 
confounding effect.
The internet-based systematic review management 
software, Covidence (Veritas Health Innovation, 
Melbourne, VIC, Australia), was used to screen titles and 
abstracts, assess full-text articles, and extract summary 
estimates from included studies. All titles, abstracts, and 
full-text articles were screened independently by pairs of 
investigators (one of JREh, JR, and JREv paired with 
one of HB, CNL, JHZ, or WW). Disagreements were 
resolved through discussion and adjudication by a third 
investigator (JREh, JR, or JREv), as needed.
This study was done as part of The Lancet Global 
Health Commission on Global Eye Health.11 The 
complete study protocol was registered prospectively at 
the Open Science Framework Registries, and has been 
published previously.12 Amendments to the initial study 
protocol are noted herein. We used the PROGRESS 
prognosis research strategy13 to develop the protocol for 
this study, which is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines (appendix pp 6–7).14
Data analysis
The following data were extracted from each publication: 
study setting; study timing; study design; sample size; 
age, gender, and ethnicity of study participants; follow-up 
time; definition of vision impairment; methods and 
eyes used for vision assessment; methods of mortality 
assessment; statistical modelling approach; and effect size 
estimates. Three pairs of investigators (JREh and CNL, JR 
and JHZ, and JREv and HB) independently extracted data 
from each article, guided by the Critical Appraisal and 
Data Extraction for Systematic Reviews of Prediction 
Modelling Studies framework.15 Disagreements were 
resolved through discussion and adjudication by a third 
investigator (JREh, JR, or JREv), as needed. When 
duplicate data were available from multiple published 
studies, preference was given to the study with the longest 
follow-up. Many studies reported results from models 
with different combinations of covariates. When estimates 
were reported with more than one level of adjustment, we 
extracted two estimates: (1) the age-adjusted estimate with 
the fewest additional covariates (minimally adjusted); and 
(2) the age-adjusted estimate with the greatest number of 
additional covariates (maximally adjusted). When multiple 
publi cations contained data from a single cohort, data 
were extracted from the publication with the longest 
follow-up. When data on multiple cohorts were presented 
in a single publication, each cohort was separately eligible 
for inclusion.
The risk of bias in included studies was assessed 
independently by three pairs of investigators (JREh and 
CNL, JR and JHZ, and JREv and HB) using the Quality 
in Prognostic Studies (QUIPS) tool.16 The following 
domains were assessed: study participation, attrition, 
prognostic factor measurement, outcome measure ment, 
confoun ding, and statistical analysis and reporting. Risk 
of bias was defined as high if a study received a high 
rating in one or more domains; low if it received a low 
rating in all six domains; or moderate if it did not meet 
criteria for low or high risk or bias. Disagreements on 
risk of bias ratings were resolved through discussion and 
adjudication by a third investigator (JREh, JR, or JREv).
We classified vision impairment according to WHO 
reporting standards: mild vision impairment (visual 
acuity <6/12 to 6/18); moderate vision impairment 
(<6/18 to 6/60); and severe vision impairment or 
blindness (<6/60). We compared the following visual 
For the study protocol see 
http://osf.io/weu96
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acuity thresholds in the meta-analysis: (1) <6/12 versus 
≥6/12; (2) <6/18 versus ≥6/18; (3) <6/60 versus ≥6/18; 
and (4) <6/60 versus ≥6/60. Note that some studies 
classified visual acuities at the category threshold as 
vision impairment, whereas others did not (eg, ≤6/12 
vs 6/12).
We did a random-effects meta-analysis to generate a 
pooled effect estimate, reported as the hazard ratio (HR) 
with 95% CIs, for the association between vision 
impairment and age-adjusted, all-cause mortality. 
Between-study heterogeneity was assessed with I² and τ² 
statistics. The primary analysis used maximally adjusted 
estimates, and the sensitivity analysis used minimally 
adjusted estimates. For studies in which only one estimate 
was available, the same estimate was used in both the 
maximally adjusted and minimally adjusted models.
We did meta-regression analyses to test whether 
effect estimates varied by the following factors: risk 
of bias, type of visual acuity chart, analysis of better-
eye data (compared with other definitions), the use of 
best-corrected visual acuity or presenting visual acuity 
as the vision assessment method, follow-up duration, a 
lower age limit (ie, participants aged <50 years vs 
those aged ≥50 years), and study design. We only did 
meta-regression analyses for studies that reported on 
the association between mortality and vision impair-
ment, defined as a visual acuity of <6/12, as there were 
too few studies to do meta-regression analyses for 
other vision impairment categories. The results are not 
reported by Global Burden of Disease Study super-
region17 as planned because all studies with a visual 
acuity <6/12 group were done in high-income countries. 
We assessed publication bias using Egger’s test 
(threshold for significance p<0·05) and by inspection of 
funnel plots. All analyses were done with Stata software, 
version 16.0.
Two investigators (JREh and JREv) graded the overall 
certainty of the evidence using the Grading of Recom-
mendations, Assessment, Development and Evaluations 
(GRADE) framework, modified for prognostic studies.18 
This instrument is used to rate the certainty of evidence 
by considering risk of bias, imprecision, inconsistency, 
indirectness, and publication bias.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
We identified 3845 articles through electronic database 
searches. After removing duplicate references, we 
screened the titles and abstracts of 2670 articles. Of these, 
we identified 76 unique studies in 92 articles for full-text 
review, during which 48 studies were excluded, leaving 
28 studies5–10,19–40 that met the inclusion criteria. Two of the 
studies each included two distinct cohorts; therefore, 
these 28 studies comprised 30 distinct cohorts (446 088 
participants) from 12 countries. 25 were observational 
cohort studies,5,6,8–10,21–40 and three were RCTs7,19,20 reporting 
an association between vision impairment and mortality 
independent of the trial interventions.
The characteristics of each cohort are reported in 
table 1. The global distribution of the included cohorts is 
shown in figure 2; there were no cohorts from eastern 
Europe, Latin America, the Caribbean, north Africa, or 
the Pacific islands.
Studies collected data between the 1970s and 2012. 
The findings from six cohorts had been published 
since 2015.5–10 The duration of follow-up among included 
studies ranged from 17 months to 210 months, with a 
mean of 103·3 (SD 46·4) months. Sample sizes ranged 
from 193 participants in Finland21 to 359 984 partici pants 
in Korea.6 24 cohorts contained an approximately equal 
number of male and female participants. However, the 
study by Pedula and colleagues22 included female 
participants only, and five other cohorts comprised less 
than 40% male participants.10,19,21,23 None of the included 
studies had less than 40% female participants, although 
one study did not report on the gender distribution of 
participants.24
Figure 1: Study selection
*Some studies were excluded for more than one reason.
3845 articles identified from peer-reviewed
databases
2670 articles identified for screening
1175 duplicates excluded
76 unique studies, reported in 92 articles,
reviewed in depth
2578 excluded after initial title and abstract 
screening
28 eligible studies (comprising 30 distinct 
cohorts)
48 studies excluded*
 11 had no age-adjusted estimates
 10 did not assess vision impairment
 8 did not adequately specify vision 
impairment
 6 included self-reported vision
impairment
 5 were commentaries on other studies
 4 did not report on association between 
vision imparment and mortality
 3 did not assess all-cause mortality
 1 reported no effect sizes
 1 was not written in English
 1 systematic review
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20 publications reported the HR as an effect estimate. 
Eight publications reported odds ratios or risk ratios of 
death for a given follow-up period. Given the high 
mortality rates in most cohorts, these estimates of effect 
size could not be considered as equivalent. Thus, meta-
analyses were done only with studies reporting HRs or 
incident rate ratios.
Measures of vision other than visual acuity were not 
commonly used. Several studies measured visual 
fields,6,23,25 contrast sensitivity,22,25 colour vision,25 and 
stereopsis.25 In this subset of studies, contrast sensitivity 
impairment, peripheral field loss, and stereoacuity 
impairment were all significantly associated with an 
increased hazard for mortality in adjusted models. 
However, because of the small number of studies that 
assessed vision using these tests, only visual acuity was 
considered in this report.
Studies used a wide variety of instruments to assess 
visual acuity. The most commonly used vision charts 
were logarithm of the minimum angle of resolution 
(n=6),5,26–30 Snellen charts (n=5),24,31–34 and Early Treatment 
Diabetic Retinopathy Study charts (n=5),7,20,35–37 whereas 
two studies did not specify the instrument used.6,23 There 
was also considerable heterogeneity in the methods used 
to define vision impairment. 15 (54%) studies used best-
corrected visual acuity to define vision impairment, and 
17 (61%) studies defined vision impairment based on 
visual acuity in the better-seeing eye.
Definitions of vision impairment also varied between 
studies. Two studies reported the association between 
mortality and a continuous measure of visual acuity.32,37 
Six other studies (comprising seven cohorts) compared a 
reference group of participants with good vision with 
groups of participants with various non-overlapping 
vision impairment categories.5,19,21,24,26,31 The remaining 
studies compared participants with visual acuity better 
than and worse than one or more visual acuity thresholds.
Studies used various strategies to assess mortality, and 
were included regardless of the methods used because 
official death registries might not have been available or 
provided high-quality data in many low-income and 
middle-income countries (LMICs).57 Most studies (n=24) 
searched official vital records, with some (n=12) also 
relying on other methods, including following up with 
participants, key informants, or both.
The pooled maximally adjusted HRs for mortality in 
adults with vision impairment compared with those who 
had better vision are shown in figure 3. The 18 cohorts 
included in the meta-analysis comprised 47 998 partici-
pants. The remaining 12 cohorts identified in the 
systematic review were not included in the meta-analysis 
for one or more of the following reasons: they used a 
vision impairment threshold that could not be aggregated 
with other studies;6 they reported results per unit 
difference in visual acuity;32,37 they reported measures of 
effect that could not be pooled with HRs;5,19,24,26,31–33,35 or 
they compared a reference category of participants with 
good vision to participants with various non-overlapping 
vision impairment categories.5,19,21,24,26,31 The associations 
between vision impairment and mortality among these 
12 cohorts are shown in table 2.
A total of 14 studies (comprising 15 cohorts) compared 
the hazard for mortality in participants with a visual 
acuity of <6/12 versus those with a visual acuity of ≥6/12; 
the adjusted HR estimate for mortality was 1·29 (95% CI 
1·20–1·39) and heterogeneity between studies was low 
Figure 2: Global distribution of included studies
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(τ²=0·01, I²=31·46%), suggesting a consistent effect 
across studies (figure 3). Two studies compared the 
hazard for mortality among participants with a visual 
acuity <6/18 versus those with a visual acuity of ≥6/18; the 
adjusted estimated HR for mortality was 1·43 (1·22–1·68) 
and heterogeneity between studies was low (τ²=0·00, 
I²=0·00%). Only one study compared the hazard for 
mortality in participants with a visual acuity of <6/60 
versus those with a visual acuity of ≥6/18, with a HR for 
mortality of 1·89 (1·45–2·47). Two studies compared the 
hazard for mortality in participants with a visual acuity of 
<6/60 versus those with a visual acuity of ≥6/60; the 
adjusted pooled HR for mortality was 1·02 (0·79–1·32; 
τ²=0·02, I²=25·04%).
The pooled minimally adjusted HR for mortality 
among participants with a visual acuity of <6/12 versus 
those with a visual acuity of ≥6/12 is shown in the 
appendix (p 8). In this analysis, the pooled minimally 
adjusted HR for mortality was 1·41 (95% CI 1·29–1·53).
For risk of bias assessment using the QUIPS tool,16 
only three studies received an assessment of low risk of 
bias across all six domains (figure 4).29,30,35 Six studies 
were assessed as having a high risk of bias in one or 
more domains.6,9,23,24,26,31
Funnel plots were reviewed for studies comparing 
all-cause mortality in participants with a visual acuity 
of <6/12 with those that had a visual acuity of ≥6/12, and 
no evidence of publication bias was identified (p=0·63; 
appendix p 9). Meta-regression analysis of studies 
comparing all-cause mortality between these two groups 
of participants revealed no evidence that the estimated 
effect size differed by risk of bias, the type of vision 
Visual acuity <6/12 vs ≥6/12
Buch et al (2005)38
Clemons et al (2004)20
Fisher et al (2014)39
Foong et al (2008)29
Karpa et al (2009)30
Knudtson et al (2006)36
Lee et al (2003)40 (African American)
Lee et al (2003)40 (non-Hispanic white people)
Liao et al (2019)8
Loprinzi et al (2016)9
Lott et al (2010)25
Ng et al (2018)10
Papudesu et al (2018)7
Pedula et al (2006)22
Siantar et al (2015)28
Heterogeneity τ²=0·01, I²=31·46%
Visual acuity <6/18 vs ≥6/18
Khanna et al (2013)27
Lott et al (2010)25
Heterogeneity τ²=0·00, I²=0·00%
Visual acuity <6/60 vs ≥6/18
Khanna et al (2013)27
Heterogeneity τ²=0·00, I²=0·00%
Visual acuity <6/60 vs ≥6/60
Agrawal et al (2011)34
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Lower mortality risk in visually
impaired individuals
Higher mortality risk in visually
impaired individuals
Figure 3: Random-effects meta-analysis results
For each study, the number of participants who died out of the total number of participants in the study is shown. Data are the maximally adjusted pooled hazard 
ratios of mortality in adults with mild vision impairment or worse (visual acuity <6/12) versus those with a visual acuity of ≥6/12; moderate vision impairment or 
worse (visual acuity <6/18) versus those with a visual acuity of ≥6/18; and severe vision impairment or blindness (visual acuity <6/60) versus those with a visual 
acuity of ≥6/18 and ≥6/60. NA=not applicable. 
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chart used, the eye assessed, follow-up duration, a lower 
age limit (ie, participants aged <50 years vs those aged 
≥50 years), or study design (table 3). However, studies 
that used best-corrected visual acuity as the vision 
assessment method reported a significantly higher 
hazard for mortality (HR 1·45 [95% CI 1·31–1·60]) than 
those using presenting visual acuity (1·22 [1·13–1·31]; 
p=0·0055).
Using the GRADE framework, we judged the evidence 
to be of moderate certainty overall, downgrading half a 
level for risk of bias and half a level for inconsistency. 
Even though only three of the 28 studies were judged as 
having a low risk of bias in all domains, meta-regression 
analyses suggested that the effect estimates were not 
associated with risk of bias. Measured inconsistency 
or heterogeneity between studies was not high, but 
there was some variation in study results. Using this 
framework, we are moderately confident that the 
mortality risk associated with vision impairment reported 
in this study is likely to be close to the true value.18
Discussion
This systematic review and meta-analysis summarises 
the existing evidence on the association between vision 
impairment and the risk of mortality among adults from 
12 countries across five continents. The results support 
the existence of a consistent association between poor 
vision and mortality across different study settings, 
thereby reinforcing the specific importance of vision and 
eye health to Sustainable Development Goal (SDG) 3, 
which aims to “ensure healthy lives and promote well-
being for all at all ages”, as well as to the SDGs more 
generally.58
This study builds on a previous meta-analysis that 
considered studies on the association between vision 
impairment and mortality published before 2015.4 This 
previous meta-analysis provided evidence that vision 
impairment could be associated with an increased risk 
of mortality; however, the study also had several key 
limitations that we sought to address in the current 
report. First, the meta-analysis included studies that not 
Reason for exclusion 
from the 
meta-analysis
Vision impairment definition (vision 
assessment method, eye) 
Comparison 
group
Minimally adjusted effect estimates 
(95% CI)*
Maximally adjusted effect 
estimates (95% CI)
Anstey et al (2001)31 Categorical analysis 6/9 (BCVA, eye NR); 6/12 (BCVA, eye NR); 
and 6/18 to 6/60 (BCVA, eye NR)
6/6 6/9, RR 0·95 (0·67–1·33); 6/12, 
1·16 (0·84–1·59); and 6/18 to 6/60, 
1·10 (0·80–1·53)
6/9, RR 0·89 (0·63–1·25); 6/12, 
1·10 (0·80–1·52); and 6/18 to 6/60, 
1·01 (0·72–1·39)
Freeman et al (2005)37 Effect estimate per 
unit change in visual 
acuity
Mild vision loss, 2–3 lines (PVA, eye NR); 
moderate vision loss, ≥3 lines (PVA, eye 
NR); and vision gain, ≥2 lines (PVA, eye 
NR) 
No change in 
visual acuity
Mild vision loss, HR 0·92 (0·61–1·37); 
moderate vision loss, 2·23 (1·43–3·46); and 
vision gain, HR 0·47 (0·23–0·96) 
Mild vision loss, HR 0·91 
(0·61–1·36); moderate vision loss, 
2·26 (1·45–3·52); and vision gain, 
0·47 (0·23–0·95)
Jacobs et al (2005)33 Did not report HRs ≤6/12 (BCVA, better eye) NA OR 2·84 (1·48–5·46)
Kim et al (2019)6 Non-standard vision 
impairment thresholds
Mild vision loss, 6/30 to 6/100 (BCVA, 
better eye) or ≤6/300 (BCVA, worse eye); 
and severe vision loss, ≤6/300 (BCVA, 
better eye) 
>6/30 Mild vision loss, HR 1·17 (0·81–1·69); and 
severe vision loss, 1·90 (1·08–3·35)
Mild vision loss, HR 1·16 
(0·81–1·67); and severe vision loss, 
1·87 (1·06–3·29)
Kulmala et al (2008)21; 
75-year-old cohort
Categorical analysis ≤6/12 to ≥6/18 (PVA, better eye); and 
<6/18 (PVA, better eye) 
>6/12 ≤6/12 to ≥6/18, HR 1·98 (1·25–3·13); and 
<6/18, 1·90 (1·12–3·20)
≤6/12 to ≥6/18, HR 2·11 (1·27–3·48); 
and <6/18, 1·34 (0·75–2·39)
Kulmala et al (2008)21; 
80-year-old cohort
Categorical analysis ≤6/12 to ≥6/18 (PVA, better eye); and 
<6/18 (PVA, better eye) 
>6/12 ≤6/12 to ≥6/18, HR 1·13 (0·74–1·72); and 
<6/18, 0·92 (0·47–1·78)
≤6/12 to ≥6/18, HR 0·77 (0·48–1·26); 
and <6/18, 0·75 (0·33–1·67)
Kuper et al (2019)5 Categorical analysis 
and did not report HRs
<6/12 to ≥6/18 (PVA, better eye); 
<6/18 to ≥6/60 (PVA, better eye); and 
<6/60 (PVA, better eye) 
≥6/12 <6/12 to ≥6/18, RR 0·92 (0·57–1·50); 
<6/18 to ≥6/60, 1·75 (1·28–2·40); and 
<6/60, 1·98 (1·04–3·80)
<6/12 to ≥6/18, RR 0·82 (0·48–1·41); 
<6/18 to ≥6/60, 1·56 (1·14–2·15); 
and <6/60, 1·46 (0·80–2·68)
Li et al (2011)26 Categorical analysis 
and did not report HRs
<6/18 to ≥3/60 (BCVA, better eye); 
<3/60 (BCVA, better eye) 
≥6/18 NA <6/18 to ≥3/60, OR 3·1 (1·5–6·4); 
and <3/60, 3·9 (2·1–7·2)
Taylor et al (2000)35 Did not report HRs ≤6/12 (BCVA, better eye) >6/12 NA OR 2·42 (1·07–5·43)
Thiagarajan et al 
(2005)19
Categorical analysis 
and did not report HRs
<6/6 to ≥6/9 (PVA, binocular); 
<6/9 to ≥6/18 (PVA, binocular); and 
<6/18 (PVA, binocular) 
≥6/6 <6/6 to ≥6/9, RR 1·10 (1·01–1·19); 
<6/9 to ≥6/18, 1·32 (1·22–1·42); and <6/18, 
1·60 (1·47–1·74)
<6/6 to ≥6/9, RR 1·06 (0·97–1·16); 
<6/9 to ≥6/18, 1·24 (1·14–1·35); and 
<6/18, 1·52 (1·39–1·66)
Thompson et al 
(1989)24
Categorical analysis 
and did not report HRs
≤6/7·5 to ≥6/9 (BCVA, better eye); 
≤6/12 to ≥6/18(BCVA, better eye); 
≤6/24 to ≥6/60 (BCVA, better eye); and 
<6/60 (BCVA, better eye)
≥6/6 NA ≤6/7·5 to ≥6/9, RR 1·62 (0·87–3·01); 
≤6/12 to ≥6/18, 1·83 (0·93–3·63); 
≤6/24 to ≥6/60, 1·72 (0·77–3·84); 
and <6/60, 0·35 (0·08–1·57)
Wang et al (2014)32 Effect estimate per 
unit difference in 
visual acuity and did 
not report HRs
(BCVA, worse eye) NA OR 1·76 (1·35–2·29) NA
The table shows effect estimates of studies that were excluded from meta-analysis, with reasons for exclusion and definitions of vision impairment. BCVA=best-corrected visual acuity. HR=hazard ratio. NA=not 
applicable. NR=not reported. OR=odds ratio. PVA=presenting visual acuity. RR=risk ratio. *All estimates are, at minimum, adjusted for age.
Table 2: Results of studies not included in the meta-analysis
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only assessed vision with objective clinical measures 
(eg, visual acuity), but also self-reported visual difficulty, 
and administrative billing codes. Because of the 
heterogeneous data, the study compared participants 
with the highest level of vision impairment to those 
with no vision impairment. This approach could have 
resulted in misclassification bias, since poor visual 
acuity, self-reported visual difficulty, and ICD codes 
could represent distinct constructs. In addition, this 
approach could have overestimated effect sizes by only 
including participants in the best and worst vision 
categories. However, in the meta-regression analyses, 
the effect size was similar for the 15 studies that assessed 
vision with visual acuity charts (relative risk 1·36 
[95% CI 1·16–1·59]), for the three studies that used ICD 
codes (1·55 [1·15–2·09]), and for the seven studies that 
used self-reported visual acuity (1·44 [1·34–1·56]). 
Another limitation of this previous meta-analysis was 
not assessing the risk of bias in included studies or not 
including an overall assessment of the certainty of the 
evidence.
The meta-analyses in our study help to quantify 
the magnitude of the association between vision 
impairment and mortality. The hazard for mortality was 
Figure 4: Risk of bias assessment
Risk of bias was assessed by use of the Quality in Prognostic Studies tool.16 Green 
represents low risk of bias, yellow represents a moderate risk of bias, and red 
represents high risk of bias. 
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HR (95% CI) p value
Risk of bias ·· ·· 0·76
Low 2 1·73 (0·85–3·50) ··
Moderate 12 1·28 (1·18–1·39) ··
High 1 1·17 (0·63–2·16) ··
Vision chart ·· ·· 0·082
ETDRS chart 3 1·46 (1·29–1·64) ··
Snellen Tumbling E chart 2 1·35 (1·14–1·61) ··
logMAR* 5 1·28 (1·17–1·40) ··
Other or not reported 5 1·12 (0·95–1·31) ··
Eye ·· ·· 0·24
Better eye 9 1·34 (1·19–1·50) ··
Other 6 1·22 (1·12–1·33) ··
Vision assessment method ·· ·· 0·0055
Best-corrected visual acuity 7 1·45 (1·31–1·60) ··
Presenting visual acuity 8 1·22 (1·13–1·31) ··
Follow-up duration, years ·· ·· 0·58
<10 7 1·35 (1·13–1·60) ··
≥10 8 1·27 (1·17–1·39) ··
Lower age limit, years ·· ·· 0·27
<50 7 1·35 (1·19–1·54) ··
≥50 8 1·24 (1·15–1·34) ··
Study design ·· ·· 0·38
Cohort 13 1·27 (1·17–1·39) ··
Randomised controlled 
trial
2 1·40 (1·18–1·66) ··
Estimated HRs for mortality in people with a visual acuity of <6/12 versus those 
with a visual acuity of ≥6/12, subcategorised by seven variables, with p values 
from the meta-regression analysis. ETDRS=Early Treatment Diabetic Retinopathy 
Study. HR=hazard ratio. logMAR=logarithm of minimum angle of resolution. 
*Includs Bailey-Lovie charts.
Table 3: Meta-regression analysis results
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29% higher for participants with a visual acuity of <6/12 
versus those with a visual acuity of ≥6/12, 43% higher 
for participants with a visual acuity of <6/18 versus 
those with a visual acuity of ≥6/18, and 89% higher for 
participants with a visual acuity of <6/60 versus those 
with a visual acuity of ≥6/18. However, there was no 
significant difference in the hazard for mortality 
between participants with a visual acuity of <6/60 versus 
those with a visual acuity of ≥6/60, probably because the 
reference group (visual acuity ≥6/60) in these studies 
contained participants with a substantial degree of 
vision impairment. Data from 12 cohorts identified in 
the systematic review could not be included in the meta-
analyses because they were not comparable with other 
included studies in terms of their analytical methods 
and categorisation of vision impairment. Among these 
heterogeneous cohorts, most (n=9) reported a significant 
association between vision impairment and increased 
mortality.
Notably, there was considerable variability in the 
methods used to assess and report visual acuity and 
mortality among included studies, which could affect 
interpretation of the findings. However, results of 
meta-regression analyses showed that the hazard for 
mortality was not significantly affected by the eye chart 
used to assess visual acuity or the eye used to assess 
the level of vision impairment (eg, the better-seeing 
eye). Nonetheless, the high degree of variability in the 
measurement and reporting of visual acuity data does 
highlight the need for widespread adoption of standard 
definitions and protocols to promote comparability 
across cohorts in future studies. The Lancet Global Health 
Commission on Global Eye Health has proposed visual 
acuity measurement and reporting standards for 
epidemiological studies, which are described in detail in 
the main Commission report.11
Meta-regression analysis revealed that the hazard for 
mortality was significantly higher in studies reporting 
best-corrected visual acuity compared with those repor-
ting presenting visual acuity as the vision assess ment 
method. This finding suggests that, compared with 
uncorrected refractive error, non-refractive causes of 
vision impairment might have a stronger association 
with mortality. This association could be due to common 
risk factors for non-refractive vision loss and mortality 
(eg, stroke or diabetes). Non-refractive vision impair-
ment could also have a greater effect on factors that 
mediate the association with mortality (eg, physical 
activity). It is also possible that some study participants 
with vision impairment due to uncorrected refractive 
error received glasses during the course of the study, 
which could have decreased their risk of vision-
impairment-related mortality. Additionally, some causes 
of vision impairment, such as cataract, glaucoma, and 
age-related macular degeneration, have been referred to 
as markers of ageing and might therefore indicate 
accelerated biological ageing.36
This systematic review and meta-analysis was limited 
by the wide variation in how studies adjusted for potential 
confounding variables, which could have biased the 
findings. Nonetheless, both maximally adjusted and 
minimally adjusted pooled effect estimates showed a 
significant association between vision impairment 
(visual acuity <6/12) and all-cause mortality. Since age is 
a strong common risk factor for both vision impairment 
and mortality, studies were only included if they reported, 
at a minimum, age-adjusted mortality. Studies also 
adjusted for other important factors that could confound 
the association between vision impairment and mortality. 
For example, socioeconomic deprivation, poor access to 
health care, diabetes, and stroke are a few of the well 
documented common risk factors for vision impairment 
and mortality,3 for which models were adjusted in many 
studies. Some studies, however, might have over-adjusted 
their statistical models, including for variables that might 
lie on the causal pathway between vision impairment 
and mortality. Adjusting for variables hypothesised to be 
on this causal pathway could bias study results toward 
the null hypothesis (ie, no effect).
Most included studies were from high-income 
countries, and additional evidence from regions not 
represented in the literature would contribute to a more 
complete understanding of this topic to inform policy. 
Future studies could also consider adopting standardised 
measurement and reporting guidelines, as outlined in 
the main Commission report.11 Furthermore, there is a 
need for studies to consider the risk of mortality 
associated with other types of vision impairment that are 
less commonly assessed, such as contrast sensi tivity 
impairment and peripheral field loss. Mediating pathways 
between vision impairment and mortality, which could 
include shared risk factors, such as physical inactivity, 
social isolation, and disability,3,59–61 should be investigated. 
Finally, future calculations of disability-adjusted life-years 
might include years of life lost due to vision impairment, 
which could provide a more complete estimate of the 
overall global burden of vision impairment.
The current study has several key strengths. First, 
we included multiple additional studies published in 
2016–19,5–10 including those from regions of the world 
that were not well represented in the previous meta-
analysis,4 such as sub-Saharan Africa (Kenya)5 and east 
Asia (South Korea).6 Second, we only included studies 
that assessed visual acuity. Even though this strategy 
might have resulted in some well designed studies being 
excluded, it served to strengthen the internal validity of 
our meta-analysis and to limit misclassification bias. 
The current investigation also included an assessment 
of the risk of bias in included studies using the well 
described QUIPS tool.16 Even though only three included 
studies were considered to have a low risk of bias across 
all domains, there was no evidence from the meta-
regression analyses that the estimated association was 
affected by risk of bias. Finally, by use of the GRADE 
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framework, an overall assessment of the strength of the 
evidence was described.
The results of this study have important implications 
for policy and practice. Worldwide, more than 80% of 
people with vision impairment and blindness live in 
LMICs, and 55% are women and girls.1 Four of five cases 
of vision impairment and blindness are preventable 
or correctable. In fact, the leading causes of vision 
impairment and blindness worldwide are cataract and 
uncorrected refractive error,62 both of which are readily 
treatable with inexpensive, cost-effective interventions.63 
Therefore, there is an important opportunity to promote 
not only health and wellbeing, but also longevity by 
correcting, rehabilitating, and preventing avoidable 
vision loss. Policies and strategies for achieving this are 
outlined in the main Commission report,11 and have the 
potential to make important contributions to achieving 
the SDGs.
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